ArticleEuropean journal of pediatrics2026
The role of N-terminal probrain natriuretic peptide in predicting Kawasaki disease shock syndrome: a prospective cohort study.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease shock syndrome (KDSS) is a severe phenotype of Kawasaki disease (KD) characterized by hemodynamic instability and systemic inflammation. Early identification of children at risk for KDSS remains challenging. N-terminal pro-B-type natriuretic peptide (NT-proBNP) reflects cardiovascular stress and has been associated with severe manifestations of KD; however, its interpretation in children is complicated by age dependency. This study aimed to evaluate the predictive utility of baseline NT-proBNP, compare raw NT-proBNP concentrations with age-adjusted NT-proBNP z-scores, and assess their performance relative to other routinely available laboratory biomarkers for KDSS prediction. A total of 588 KD patients were finally enrolled in this prospective cohort study between January 2015 and March 2021. The demographic/clinical characteristics and laboratory data were compared between the patients with KDSS (KDSS group, n = 35) and those without (KD group, n = 553). NT-proBNP concentrations were analyzed as both raw values and age-adjusted z-scores calculated using established pediatric reference ranges. Multivariable logistic regression models were constructed using baseline variables, with log10-transformed NT-proBNP and NT-proBNP z-score evaluated in separate models. Receiver operating characteristic (ROC) analyses were performed to compare predictive performance among NT-proBNP-related parameters and other candidate biomarkers. Children in the KDSS group were older than those in the non-KDSS group (66.11 ± 47.06 vs. 31.36 ± 23.57 months, P < 0.001). KDSS patients had significantly higher rates of coronary artery lesions (40.0% vs. 11.6%, P < 0.001) and intravenous immunoglobulin (IVIG) resistance (51.5% vs. 12.5%, P < 0.001), while classic clinical manifestations such as bilateral conjunctival injection (74.3% vs. 92.8%, P = 0.001) and oral mucosal erythema (77.1% vs. 93.1%, P = 0.004) were less frequent. Regarding laboratory parameters, KDSS patients exhibited significantly higher neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-albumin ratio (CAR), creatinine, and NT-proBNP, but significantly lower lymphocyte-to-C-reactive protein ratio (LCR), hemoglobin, platelet count, hematocrit, sodium, and potassium levels compared with non-KDSS patients. Multivariate logistic regression identified older age, higher NT-proBNP (both raw and age-standardized Z-score), lower platelet, hemoglobin, and rates of erythema of oral and pharyngeal mucosa as independent predictors of KDSS. ROC analysis showed that the raw NT-proBNP cutoff of 1354 pg/mL gave an AUC of 0.71 (95% CI 0.61-0.81), with sensitivity of 74.3% and specificity of 64.2%, and age-standardized NT-proBNP Z-score had an AUC of 0.73 (95% CI 0.63-0.83), with an optimal cutoff of ≥ 3.3 yielding a sensitivity of 74.3% and specificity of 65.8%.
conclusionNT-proBNP might be a complementary laboratory marker for the prediction of KDSS in KD. WHAT IS KNOWN: • NT-proBNP concentrations are age-dependent in children, but most previous studies of KDSS have relied on absolute NT-proBNP concentrations without age-standardized interpretation. WHAT IS NEW: • Baseline NT-proBNP was independently associated with KDSS, and age-adjusted NT-proBNP z-scores showed comparable predictive performance, supporting NT-proBNP as an adjunctive marker for early KDSS risk stratification after consideration of age dependency.
Indexed as
Identifiers
42711435What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.